Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

Cell imaging often relies on synthetic or genetic fluorescent labels, to provide contrast which can be far from ideal for imaging cells in their in vivo state. We report on the biological application of a label-free, high contrast microscopy technique known as ptychography, in which the image producing step is transferred from the microscope lens to a high-speed phase retrieval algorithm.

From Phase Focus Limited 28 Jan 2014

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

Porvair Sciences has announced a new Chromatrap Enzymatic Shearing Kit that contains all the necessary reagents and buffers for up to 10 chromatin preparations.

From Chromatrap® - Porvair Sciences Ltd 27 Jan 2014

ADDF, Alzheimer's Society partner to provide funding for research in Alzheimer's disease

Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

24 Jan 2014

Next-generation high content screening system launched by PerkinElmer

PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, has announced the launch of the Opera Phenix™, a next-generation, confocal, high-content screening system that will enable scientists to perform the most challenging applications with greater speed and sensitivity, accelerating the understanding of disease and discovery of new and more effective treatments.

23 Jan 2014

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound.

23 Jan 2014

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

The Institute of Cancer Research, London, Cancer Research Technology, London and Nuevolution A/S, Copenhagen have entered into a drug discovery collaboration to identify novel lead candidates for cancer treatment.

23 Jan 2014

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

21 Jan 2014

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.

20 Jan 2014

Axxam, Cellectis bioresearch partner to offer cell-based assays to Life Science industry

Axxam (Milan), a leading provider of discovery services including assay development for high-throughput screening, and Cellectis bioresearch (Paris), the cell engineering expert, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies.

19 Jan 2014

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury.

13 Jan 2014

Virginia Tech engineer receives NSF RAPID grant to study effects of antibiotic resistance genes on Colorado flood

The World Health Organization and the Center for Disease Control has recognized antibiotic resistance "as a critical health challenge of our time," said Amy Pruden, a Virginia Tech environmental engineer who is credited with pioneering the concept of antibiotic resistance genes as environmental pollutants.

10 Jan 2014

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

8 Jan 2014

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Fungi have played a large role in the development of many important drugs that are in wide use today. The most well-known of these are the penicillins.

7 Jan 2014

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, and Mirna Therapeutics, Inc., a privately-held biotechnology company pioneering microRNA replacement therapy for cancer, announced today that they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna's proprietary microRNAs and Marina Biotech's novel SMARTICLES liposomal delivery technology.

3 Jan 2014

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

A compound derived from a traditional Chinese herbal medicine has been found effective at alleviating pain, pointing the way to a new nonaddictive analgesic for acute inflammatory and nerve pain, according to UC Irvine pharmacology researchers.

3 Jan 2014

Genetics of rheumatoid arthritis contributes to biology and drug discovery

The results of the largest international study to date into the genetic basis of rheumatoid arthritis shed light on the biology of the disease and provide evidence that large-scale genetic studies can assist in the identification of new drugs for complex disorders such as rheumatoid arthritis.

26 Dec 2013

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.

24 Dec 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Drug Discovery News and Research

Further Reading

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

ADDF, Alzheimer's Society partner to provide funding for research in Alzheimer's disease

Next-generation high content screening system launched by PerkinElmer

Scientists develop new genetic platform that yields novel antibiotic from ocean bacteria

ICR, Nuevolution and CRT partner to identify novel drug candidates for cancer treatment

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Axxam, Cellectis bioresearch partner to offer cell-based assays to Life Science industry

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Virginia Tech engineer receives NSF RAPID grant to study effects of antibiotic resistance genes on Colorado flood

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Crowdsourcing fungal metabolites with antitumor activity: an interview with Dr. Robert H. Cichewicz, University of Oklahoma

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Chinese herbal medicine effective at alleviating acute inflammatory and nerve pain

Genetics of rheumatoid arthritis contributes to biology and drug discovery

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News